Tissue factor-positive microparticles: Cellular origin and association with coagulation activation in patients with colorectal cancer

Summary

The pathogenesis of hypercoagulability in cancer is not entirely understood. We hypothesized that in cancer patients circulating tissue factor-positive microparticles (TF⁺ MPs) are increased and associated with hemostatic system activation. In 20 patients with advanced colorectal cancer and in 20 age- and sex-matched controls, number and cellular origin of TF⁺ MPs were determined in plasma by flow cytometry. D-dimer was determined as an indicator of hemostatic system activation. Compared to controls, the median (interquartile range) number of TF⁺ MPs was two-fold higher in cancer patients: 25.9 (15.4 – 42.0) × 10³ /ml plasma versus 13.1 (11.9 – 19.7) × 10³ /ml plasma, p = 0.007. This was mainly due to a higher amount of TF⁺ MPs from platelets (13.4 [5.0 – 17.4] × 10³ /ml plasma vs. 5.8 [4.5 – 7.5] × 10³ /ml plasma, p = 0.017). TF⁺ MPs correlated with D-dimer (ρ = 0.48, p = 0.002). High levels of TF⁺ MPs in cancer patients and their correlation with D-dimer suggest that TF⁺ MPs might be involved in hemostasis activation in cancer patients.

Keywords

Cancer - microparticles - tissue factor - hemostasis - platelets

• References

• 1 Heit JA, Silverstein MD, Mohr DN. et al Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809-15.
• 2 Baron JA, Gridley G, Weiderpass E. et al Venous thromboembolism and cancer. Lancet 1998; 351: 1077-80.
• 3 Sorensen HT, Mellemkjaer L, Olsen JH. et al Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-50.
• 4 Sallah S, Husain A, Sigounas V. et al Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res 2004; 10: 7238-43.
• 5 Oya M, Akiyama Y, Okuyama T. et al High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol 2001; 31: 388-94.
• 6 Iversen LH, Okholm M, Thorlacius-Ussing O. Preand postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease – a preliminary study. Thromb Haemost 1996; 76: 523-8.
• 7 Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992; 70: 1194-201.
• 8 Nakasaki T, Wada H, Shigemori C. et al Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 2002; 69: 247-54.
• 9 Boccaccio C, Sabatino G, Medico E. et al The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005; 434: 396-400.
• 10 Bogdanov VY, Balasubramanian V, Hathcock J. et al Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9: 458-62.
• 11 Rauch U, Antoniak S, Boots M. et al Association of tissue-factor upregulation in squamous-cell carcinoma of the lung with increased tissue factor in circulating blood. Lancet Oncol 2005; 6: 254
• 12 Diamant M, Tushuizen ME, Sturk A. et al Cellular microparticles: new players in the field of vascular disease?. Eur J Clin Invest 2004; 34: 392-401.
• 13 Biro E, Sturk-Maquelin KN, Vogel GM. et al Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost 2003; 1: 2561-8.
• 14 Chou J, Mackman N, Merrill-Skoloff G. et al Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004; 104: 3190-7.
• 15 Combes V, Simon AC, Grau GE. et al In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104: 93-102.
• 16 Chirinos JA, Heresi GA, Velasquez H. et al Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol 2005; 45: 1467-71.
• 17 Rauch U, Bonderman D, Bohrmann B. et al Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000; 96: 170-5.
• 18 Yu JL, May L, Lhotak V. et al Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105: 1734-41.
• 19 Seto S, Onodera H, Kaido T. et al Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer 2000; 88: 295-301.
• 20 Haas SL, Jesnowski R, Steiner M. et al Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol 2006; 12: 4843-9.
• 21 Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004; 2: 2065-7.
• 22 Antal-Szalmas P, Strijp JA, Weersink AJ. et al Quantitation of surface CD14 on human monocytes and neutrophils. J Leukoc Biol 1997; 61: 721-8.
• 23 Østerud B.. Tissue factor in neutrophils: no J Thromb Haemost. 2004; 2: 218-20.
• 24 Cosmi B, Legnani C, Cini M. et al The role of D-dimer and residual venous obstruction in recurrence of venous thromboembolism after anticoagulation withdrawal in cancer patients. Haematologica 2005; 90: 713-15.
• 25 Berckmans RJ, Neiuwland R, Boing AN. et al Cellderived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 85: 639-46.
• 26 Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006; 26: 456-61.
• 27 Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001; 102: V215-24.
• 28 Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 2003; 124: 58S-68S.